A fixed-dose combination (FDC) of a broad-spectrum fluoroquinolone antibiotic (Ofloxacin) and an antimuscarinic, antispasmodic agent (Flavoxate). It is primarily indicated for the treatment of uncomplicated urinary tract infections (UTIs) and associated symptoms like dysuria, urgency, and frequency. The combination aims to provide both antibacterial action against common uropathogens and symptomatic relief from bladder spasms. This FDC is widely used in the Indian outpatient setting for empirical therapy of lower UTIs.
Adult: One tablet (Ofloxacin 200mg + Flavoxate 200mg) twice daily. Typically prescribed for 3-7 days for acute uncomplicated UTI.
Note: Take tablet with a full glass of water, with or without food (taking with food may minimize GI upset). Maintain adequate hydration. Do not crush or chew. Complete the full prescribed course even if symptoms improve early.
Ofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. This leads to rapid bactericidal activity. Flavoxate is a competitive muscarinic receptor antagonist with direct papaverine-like smooth muscle relaxant activity on the urinary tract, relieving spasm and associated symptoms.
Pregnancy: CONTRANDICATED (Pregnancy Category C for Ofloxacin). Animal studies show cartilage damage in immature animals. Flavoxate safety not established. Risk outweighs benefit.
Driving: May impair alertness, coordination, and vision due to dizziness, drowsiness, or blurred vision (Flavoxate effect). Patients should not drive or operate machinery until their response is known.
| Antacids (Al, Mg, Ca), Sucralfate, Iron/Zinc supplements | Markedly reduce absorption of Ofloxacin due to chelation | Major |
| NSAIDs (e.g., Ibuprofen, Diclofenac) | Increased risk of CNS stimulation and seizures | Major |
| Corticosteroids (e.g., Prednisolone) | Increased risk of tendon rupture | Major |
| Other QT-prolonging drugs (Amiodarone, Sotalol, Macrolides, TCAs) | Additive risk of torsades de pointes | Major |
| Warfarin | Ofloxacin may enhance anticoagulant effect, increasing INR | Moderate |
| Theophylline | Ofloxacin may increase Theophylline levels, risk of toxicity | Moderate |
| Oral Hypoglycemics (e.g., Glimepiride) / Insulin | Ofloxacin may cause hypo- or hyperglycemia | Moderate |
| Other Anticholinergics (e.g., Atropine, Dicyclomine, TCAs) | Additive anticholinergic side effects with Flavoxate | Moderate |
Same composition (Ofloxacin (200mg) + Flavoxate (200mg)), different brands: